Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgery

Br J Ophthalmol. 2014 Oct;98(10):1320-4. doi: 10.1136/bjophthalmol-2014-304902. Epub 2014 Apr 1.

Abstract

The management of antiplatelet and anticoagulant treatment can be challenging for the ophthalmic surgeon with the risk of impaired surgical view or potentially sight-threatening haemorrhage. With the advent of newer medications and the expanding usage of these drugs, there is a need for up-to-date guidance on the subject. This paper describes the current use of modern antiplatelet and anticoagulant drugs in the UK, and reviews the evidence of such treatments in the context of ophthalmic surgery. A multidisciplinary approach has been used to develop a guideline for the management of antiplatelet and anticoagulation treatment in elective ophthalmic surgery. Specifically, guidance is provided on when and how to stop antiplatelet and anticoagulant treatment and, importantly, when to seek specialist medical advice.

Keywords: Biochemistry; Diagnostic tests/Investigation; Treatment Surgery.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use*
  • Elective Surgical Procedures*
  • Humans
  • Intraoperative Complications / prevention & control
  • Ophthalmologic Surgical Procedures*
  • Platelet Aggregation Inhibitors / therapeutic use*

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors